Physician profile
Mark Anthony Pinto
NPI 1801882360
$590.85
in general payments reported to CMS, 2019-2025
18 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.72 · 2020: $41.07 · 2021: $12.88 · 2022: $114 · 2023: $57.24 · 2024: $147 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $329.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $87.22 | 2024-2025 | |
| Lilly USA, LLC | $63.96 | 2019-2024 | Mounjaro, Zepbound |
| Biohaven Pharmaceutical Holding Company Ltd. | $61.30 | 2022 | |
| Sanofi Pasteur INC. | $44.48 | 2022-2023 | |
| Amgen INC. | $42.04 | 2019-2025 | Krystexxa |
| Novo Nordisk INC | $36.97 | 2023-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $35.70 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $30.58 | 2025 | Breztri |
| Glaxosmithkline, LLC. | $28.04 | 2019-2025 | Penmenvy, Bexsero |
| Ultragenyx Pharmaceutical INC. | $26.92 | 2024 | Crysvita |
| Aimmune Therapeutics, INC. | $21.16 | 2024 | |
| Coopersurgical, INC. | $20.84 | 2020 | |
| Pfizer INC. | $20.51 | 2025 | |
| Exact Sciences Corporation | $16.02 | 2024 | Cologuard Collection Kit |
| Cranial Technologies, INC | $14.73 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vbi Vaccine (Delaware) INC. | $14.36 | 2023 | Prehevbrio |
| Roche Diagnostics Corporation | $13.14 | 2019 | |
| Phadia US INC. | $12.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pinto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.